Circulating tumor markers: Liquid biopsy as a non-invasive diagnostic tool.

Armin Illert*

Department of Oncology, University College Cork, Ireland

Introduction

Cancer diagnosis and monitoring have traditionally relied on tissue biopsies, which, while effective, are invasive and may not always be feasible. In recent years, liquid biopsy has emerged as a promising alternative, allowing for the detection of circulating tumor markers in bodily fluids such as blood, urine, and saliva. These markers, including circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles, provide valuable insights into cancer progression, treatment response, and minimal residual disease [1].

Circulating tumor markers are biomolecules released by cancer cells into the bloodstream. They include proteins, nucleic acids, and whole tumor cells that can be detected and analyzed for diagnostic and prognostic purposes. Unlike traditional biopsies, which provide a single snapshot of the tumor at one point in time, liquid biopsies enable continuous monitoring of the disease, offering a dynamic view of cancer progression [2].

Liquid biopsy offers several advantages over conventional tissue biopsy. It is minimally invasive, reducing patient discomfort and the risk of complications. Additionally, it enables real-time monitoring of tumor evolution, making it particularly useful for detecting early signs of resistance to therapy. Furthermore, liquid biopsy can capture tumor heterogeneity, as it reflects genetic material from different tumor sites within the body, unlike a single-tissue biopsy that may not fully represent the cancer's complexity [3].

The use of liquid biopsy is expanding in clinical oncology, with applications in early cancer detection, prognosis, treatment selection, and monitoring. For example, in lung cancer, the detection of EGFR mutations in ctDNA helps guide targeted therapy decisions. Similarly, in breast cancer, CTC analysis can provide prognostic information, helping oncologists tailor treatment plans [4].

One of the most valuable aspects of liquid biopsy is its ability to track treatment response. By analyzing ctDNA levels, clinicians can determine whether a patient is responding to therapy or if the cancer is developing resistance. This allows for timely adjustments to treatment plans, improving patient outcomes. In cases where minimal residual disease (MRD) is present, liquid biopsy can detect traces of cancer that may lead to recurrence, enabling early intervention [5].

Metastatic cancers pose significant challenges in treatment due to their complexity and genetic diversity. Liquid biopsy provides a means to assess tumor evolution in real time, offering insights into emerging mutations that drive resistance. This is particularly relevant in cancers such as melanoma, colorectal cancer, and prostate cancer, where liquid biopsy can guide the selection of second-line and third-line therapies [6].

Despite its advantages, liquid biopsy also has limitations. One challenge is the low concentration of circulating tumor markers, which can make detection difficult, particularly in early-stage cancers. Additionally, standardization of testing methods remains a concern, as different assays may yield varying results. The cost of liquid biopsy is another factor that limits its widespread adoption, though ongoing research aims to improve accessibility and affordability [7].

Recent advancements in liquid biopsy technology, such as next-generation sequencing (NGS) and digital PCR, have significantly improved the sensitivity and accuracy of detecting tumor markers [8].

Ongoing research is focused on integrating liquid biopsy into routine clinical practice, with efforts to develop standardized guidelines for its use. Future developments may include the combination of liquid biopsy with artificial intelligence (AI) to enhance data analysis and predictive modelling [9].

The rise of personalized medicine has further emphasized the importance of liquid biopsy. By identifying specific genetic mutations in a patient’s tumor, liquid biopsy enables the selection of targeted therapies that are most likely to be effective. This individualized approach minimizes unnecessary treatments and reduces side effects, ultimately improving patient outcomes [10].

Conclusion

Liquid biopsy represents a groundbreaking advancement in oncology, offering a non-invasive, real-time method for detecting and monitoring cancer. With its potential to revolutionize early diagnosis, treatment selection, and disease monitoring, liquid biopsy is paving the way for a more personalized and precise approach to cancer care. While challenges remain, continued research and technological advancements will likely establish liquid biopsy as a routine tool in oncology, transforming the landscape of cancer diagnosis and treatment.

***Correspondence to:** Armin Illert, Department of Oncology, University College Cork, Ireland. E-mail: armin.illert@ucc.ie

Received: 1-Mar-2025, Manuscript No. JMOT-25-162123; **Editor assigned:** 4-Mar-2025, PreQC No. JMOT-25-162123 (PQ); **Reviewed:** 17-Mar-2025, QC No. JMOT-25-162123; **Revised:** 24-Mar-2025, Manuscript No. JMOT-25-162123 (R); **Published:** 31-Mar-2025, DOI: 10.35841/jmot-10.2.257

Citation: *Illert A. Circulating tumor markers: Liquid biopsy as a non-invasive diagnostic tool. J Med Oncl Ther. 2025;10(2):257.*

References

1. Marrugo-Ramírez J, Mir M, Samitier J. Blood-based cancer biomarkers in liquid biopsy: A promising non-invasive alternative to tissue biopsy. Int J Mol Sci. 2018;19(10):2877.
2. Heidrich I, Abdalla TS, Reeh M, et al. Clinical applications of circulating tumor cells and circulating tumor DNA as a liquid biopsy marker in colorectal cancer. Cancers. 2021;13(18):4500.
3. Soda N, Rehm BH, Sonar P, et al. Advanced liquid biopsy technologies for circulating biomarker detection. J Mater Chem B. 2019;7(43):6670-704.
4. Michela B. Liquid biopsy: A family of possible diagnostic tools. Diagnostics. 2021;11(8):1391.
5. Elazezy M, Joosse SA. Techniques of using circulating tumor DNA as a liquid biopsy component in cancer management. Comput Struct Biotechnol J. 2018;16:370-8.
6. Toledano-Fonseca M, Cano MT, Inga E, et al. Circulating cell-free DNA-based liquid biopsy markers for the non-invasive prognosis and monitoring of metastatic pancreatic cancer. Cancers. 2020;12(7):1754.
7. Allen TA. The role of circulating tumor cells as a liquid biopsy for cancer: Advances, biology, technical challenges, and clinical relevance. Cancers. 2024;16(7):1377.
8. Adhit KK, Wanjari A, Menon S, et al. Liquid biopsy: An evolving paradigm for non-invasive disease diagnosis and monitoring in medicine. Cureus. 2023;15(12).
9. Chen K, Sun J, Zhao H, et al. Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy. Mol Cancer. 2021;20:1-7.
10. Wu X, Li J, Gassa A, et al. Circulating tumor DNA as an emerging liquid biopsy biomarker for early diagnosis and therapeutic monitoring in hepatocellular carcinoma. Int J Biol Sci 2020;16(9):1551.

Citation: *Illert A. Circulating tumor markers: Liquid biopsy as a non-invasive diagnostic tool. J Med Oncl Ther. 2025;10(2):257.*